Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
Baltà-Cruz
Susana
S
Alsina-Glbert
Mercé
M
Mozos-Rocafort
Ana
A
Cervera
Carlos
C
Colomo-Saperas
Lluís
L
Del Río
Ana
A
Estrach-Panella
Teresa
T
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016773:Leishmaniasis, Cutaneous / Q000150:complications* / Q000175:diagnosis / Q000473:pathology; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab